Archived NCCN Tumor Boards: Induction Therapy for Ph+ B-Cell Acute Lymphoblastic Leukemia

The NCCN Guidelines® for Acute Lymphoblastic Leukemia provide evidence-based, consensus-driven recommendations to guide cancer prevention, diagnosis, treatment, and supportive care, and are regularly updated to reflect emerging data to support oncology health care professionals in making informed clinical decisions.

This session will provide education on lower intensity and even chemotherapy-free induction therapies, such as blinatumomab combined with a TKI, may help to minimize treatment-related adverse effects while maintaining efficacy.

Target Audience

This educational program is designed to meet the educational needs of physicians/oncologists, nurse practitioners, nurses, physician assistants/associates, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Discuss results of clinical trials assessing lower intensity induction therapy options for newly diagnosed Ph-positive B-ALL.
  • Identify treatment-related adverse events of agents commonly used in induction therapy for Ph-positive B-ALL, such as TKIs and blinatumomab.
  • Compare and contrast TKI options for newly diagnosed Ph-positive B-ALL.

You may also be interested in

Recorded Presentation of NCCN Optimizing Patient Outcomes - In a Blink of an Eye: Updates in Frontline Therapy with Blinatumomab for Pediatric Acute Lymphoblastic Leukemia

ALL in the pediatric patient demographic has demonstrated a growing improvement in survival rates over the past five decades. However, challenges in management approaches and prognoses persist.
Additional information
Supporters: 
This activity is supported by educational grants from:
  • AstraZeneca
  • Johnson & Johnson
  • Lilly
  • Novartis
  • Nuvalent, Inc. 
Supported by an education grant from Nuvation Bio. 
 
This activity is supported by independent educational grants from:
  • Merck & Co., Inc., Rahway, NJ, USA.
  • Regeneron Pharmaceuticals, Inc. 

Course summary

Available credit: 
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Course opens: 
10/13/2026
Course expires: 
10/08/2027
Part of: 
Archived NCCN Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care
Presenters
 
Aaron C. Logan, MD, PhD, MPhil
UCSF Helen Diller Family Comprehensive Cancer Center
 
Mimi Lo, PharmD, BCPS, BCOP
UCSF Helen Diller Family Comprehensive Cancer Center  
 
NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.
 
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 
 
Definitions
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
 
Faculty Disclaimers  
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery. Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
 
Faculty Disclosures
The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
 
Aaron C. Logan, MD, PhD, MPhil
Amgen Inc.: Consulting Fee; Grant/Research Support 
Ascentage Pharma: Consulting Fee
Autolus Therapeutics: Grant/Research Support 
Kite Pharma: Grant/Research Support 
Orca Bio: Consulting Fee
sanofi-aventis U.S.: Consulting Fee 
Syndax Pharmaceuticals: Consulting Fee
 
Mimi Lo, PharmD, BCPS, BCOP
sanofi-aventis U.S.: Honoraria
 
NCCN Staff Disclosures
None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing health care products by or on patients.
image

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physicians
NCCN designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 1.0 contact hour.

Pharmacists
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-26-105-H01-P

Physician Associates
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until October 8, 2027. PAs should only claim credit commensurate with the extent of their participation.

Case Managers
This program has been pre-approved by The Commission to provide continuing education credit to CCM® Board-Certified Case Managers. The course is approved for 1.0 CE contact hour. Activity Code: S00068690; Approval Number: 260002775
 
To claim these CEs, log into your dashboard at www.yourcommission.org.  

Available Credit

  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Please login or register to take this course.

Required Hardware/software

To complete this activity, you will need: 

  • A device with an Internet connection and sound playback capability (speakers or a headset) 
  • Adobe Reader or other PDF reader software for certificate viewing/printing